Myocardial electrophysiological properties in the presence of an AT1 angiotensin II receptor antagonist

Basic Research in Cardiology

Volumn 92, Issue 3, 1997, Pages 129-138

  Cox, M H ^a   O S J , ^a   De Gasparo, M ^c   Mukherjee, R ^a   Hewett, K W ^b   Spinale, F G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c CIBA GEIGY LTD   (Switzerland)

Author keywords

Angiotensin II; AT1 angiotensin II receptor blockade; Myocardial electrophysiology

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; VALSARTAN;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GUINEA PIG; HEART ELECTROPHYSIOLOGY; HEART MUSCLE; MEMBRANE POTENTIAL; MEMBRANE STEADY POTENTIAL; MICROELECTRODE; NONHUMAN; RAT; REPOLARIZATION; SARCOLEMMA;

EID: 8544230611     PISSN: 03008428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00788630     Document Type: Article

References (39)

1. Atkinson AB, Robertson JIS (1979) Captopril in the treatment of clinical hypertension and cardiac failure. Lancet 2: 836-839
2. Bonnardeaux JL, Park WK, Regoli D (1977) Effects of angiotensins and catecholamines on the transmembrane potential and isometric force of rabbit isolated atria. Arch Int Pharmacodyn 229: 83-94
3. Brachman J, Scherlag B, Rosenstraukh LV, Lazzara R (1983) Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation 68: 846-856
4. Brink M, de Gasparo M, Whitebread S, Bullock G (1995) Localization of angiotensin II receptor subtypes in the rabbit heart. J Mol Cell Cardiol 27: 459-470
5. Captopril Multicenter Research Group (1984) A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 2: 755-763
6. 1-receptor subtype. Br J Pharmacol 110: 761-771
7. Dangman KH, Hoffman BF (1981) In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide. J Pharmacol Exp Ther 217: 851-862
8. De Gasparo M, Rogg H, Brink M, Wang L, Whitebread S, Bullock G, Erne P (1994) Angiotensin II receptor subtypes and cardiac function. Eur Heart J 15: 98-103
9. De Mello WC, Crespo MJ (1995) Cardiac refractoriness is reduced by angiotensin II. J Cardiovasc Pharmacol 25: 51-56
10. Elharrar V, Surawicz B (1983) Cycle length effect on restitution of action potential duration in dog cardiac fibers. Am J Physiol 244: H782-H792
11. Enous R, Coetzee WA, Opie LH (1992) Effects of the ACE inhibitor, perindoprilat, and of angiotensin II on the transient inward current of guinea pig ventricular myocytes. J Cardiovasc Pharmacol 19: 17-23
12. Freer RJ, Pappano AJ, Peach MJ, Bing KT, McLean MJ, Vogel S, Sperelakis N (1976) Mechanism for the positive inotropic effect of angiotensin II on isolated cardiac muscle. Circ Res 39: 178-183
13. Hermsmeyer K (1980) Angiotensin II increases electrical coupling in mammalian ventricular myocardium. Circ Res 47: 524-529
14. Hewett KW, Gaymes CH, Noh C-I, Ross BA, Thompson RA, Buckles DS, Gillette PC (1991) Cellular electrophysiology of neonatal and adult rabbit atrioventricular node. Am J Physiol 260: H1674-H1684
15. Holubarsch C, Hasenfuss G, Schmidt-Schweda S. Knorr A, Pieske B, Ruf T, Fasol R, Just H (1993) Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium: an in vitro study under physiological experimental conditions. Circulation 88: 1228-1237
16. Iven H, Zetler G (1980) Failure of peptides (angiotensin, bradykinin, substance P, physalaemin, met-enkephalin) to influence the cardiac action potential. Pharmacology 21: 403-406
17. Johannsson M, Asgrimsson H (1989) Short-term effects of stimulus interval changes in guinea-pig and rat atrial muscle. Acta Physiol Scand 135: 73-81
18. Katzung BO, Morgenstern JA (1977) Effects of extracellular potassium on ventricular automaticity and evidence for a pacemaker current in mammalian ventricular myocardium. Circ Res 40: 105-111
19. Klitzman B, Popel AS, Duling BR (1983) Oxygen transport in resting and contracting hamster cremaster muscles: Experimental and theoretical microvascular studies. Microvasc Res 25: 108-131
20. 1 AT-II) blockade on myocyte excitation and contraction in dilated cardiomyopathy. J Am Col Cardiol (Abstract): 133A
21. Müller P, Cohen T, de Gasparo M, Sioufi A, Racine-Poon A. Howald H (1994) Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 47: 231-245
22. K and enhancement of the L-type calcium current in guinea pig ventricular myocytes. Cardiovasc Res 28: 201-208
23. Regitz-Zagrosek V, Friedel N, Heymann A, Bauer P, Neuß M, Rolfs A, Steffen C, Heldebrandt A, Hetzer R, Fleck E (1995) Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation 91: 1461-1471
24. Robinson RB, Boyden PA, Hoffman BF, Hewett KW (1987) Electrical restitution process in dispersed canine cardiac Purkinje and ventricular cells. Am J Physiol 253: H1018-H1025
25. Rogg H, Schmid A, de Gasparo M (1990) Identification and characterization of angiotensin II receptor subtypes in rabbit ventricular myocardium. Biochem Biophys Res Comm 173: 416-422
26. Sechi LA, Griffin CA, Grady EF, Kalinyak JE, Schambelan M (1992) Characterization of angiotensin II receptor subtypes in rat heart. Circ Res 71: 1482-1489
27. SOLVD Investigators (1991) Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293-302
28. Steel RGD, Torrie JH (1980) Principles and procedures of statistics: a biomedical approach. New York: McGraw-Hill: 172-553
29. Strauss HC, Bigger JT Jr, Hoffman BF (1970) Electrophysiological and betareceptor blocking effects of MJ 1999 on dog and rabbit cardiac tissues. Circ Res 26: 661-678
30. Surawicz B, Imanishi S (1976) Automatic activity in depolarized guinea pig ventricular myocardium: characteristics and mechanisms. Circ Res 39: 751-759
31. The Consensus Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 23: 1429-1435
32. Tood PA, Heel RC (1986) Enalapril: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 31: 198-248
33. 2+ transients in neonatal and adult cardiomyocytes by angiotensin II and endothelin-1. Am J Physiol 270: H857-H868
34. Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, Yoshinaga K (1993) Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1: 28-32
35. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A (1990) Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 66: 883-890
36. 1 receptor antagonist irbesartan in hypertension. Hypertension 25: 22-29
37. Wong PC, Price WA Jr, Chiu AT, Carini DJ, Duncia JR, Johnson AL, Wexler RR (1990) Timmermans PBMWM. Nonpeptide angiotensin II receptor antagonist: studies with EXP 9270 and DuP 753. Hypertension 15: 823-834
38. Yang T, Tande PM, Lathrop DA, Refsum H (1992) Effects of altered extracellular potassium and pacing cycle length on the class III antiarrhythmic action of dofetilide (UK-68,798) in guinea-pig papillary muscle. Cardiovasc Drugs Ther 6: 429-436
39. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaife RA, Lowes BD, Roden RL, Peacock SJ, Groves RM, Raynolds MV, Bistow MR, Perryman MB (1995) Angiotensin II formation in the intact human heart: predominance of the angiotensin-converting enzyme pathway. J Clin Invest 95: 1490-1498